Yes. Our workflow blends both approaches: the AI generates optimized sequences, and our wet-lab team produces and tests 20 variants per round. We can run up to three cycles to reach the affinity improvement you’re aiming for.

We can work with virtually any format, including IgG, Fab, scFv, VHH, bispecifics, and Fc-engineered molecules.

It is possible, but these targets often require additional attention. We assess each project individually to confirm feasibility before moving forward.

Yes. Our algorithms evaluate multiple properties at once, including developability, so the selected variants strike the right balance between performance and stability.

Most projects are completed within 6 to 10 weeks, depending on the level of optimization required.

We produce and analyze 20 variants for each optimization cycle.

We simply need the amino-acid sequence of your antibody and its antigen to begin the optimization process.

Our service is fully guaranteed. If we cannot deliver at least a 10-fold improvement, you do not pay for the full service.

Yes. If affinity cannot be improved through the standard workflow, we can suggest an alternative strategy or continue the optimization without additional cost.

We monitor these parameters from the earliest design steps and validate them experimentally in the final stages, ensuring that selected variants meet all quality criteria.

Absolutely. The service is 100% IP-free, and all sequences belong to you once the project is completed.

No. We rely entirely on proprietary models, and there are no licensing fees. You only pay for the service itself.

You receive a detailed report, the AI-generated sequences, production and QC data, up to 1 mg of purified antibody for each of the 20 variants, and full intellectual-property ownership.

We guarantee at least a 10-fold improvement, and many projects reach between 100- and 1,000-fold increases.

Yes. It integrates seamlessly with our entire suite of services, including custom antibody development, antibody humanization service, custom recombinant antibody production, custom cell line development, and developability assessment services.